← Leaderboards
Jason Andrew Somarelli
Duke University
$513,091
Attributed
$1,026,182
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $419.1K · FY2023–25$500K$375K$250K$125K$0
'23
'24
'25
Funding mix
By agency
NIH$1,026,182 · 2
By mechanism
R25$632,297 · 1
R21$393,885 · 1
Top collaborators
- Gerard C Blobe3 shared
- Amanda E Hargrove2 shared
Most similar at Duke University
Same institution · by research overlap
- Michael Barry Kastan$65,974,699
- Steven R Patierno$12,611,775
- Jeffrey None Crawford$10,066,024
- Hrishikesh Chakraborty$16,373,642
- David M. Ashley$7,073,119
Others in their field
Other Rising Stars on “Cause Of Death”
- Chris Maxwell · National Institute Of Allergy And Infectious Diseases$12,000,000
- Warwick Britton · University Of Sydney$10,964,476
- John Alam · Eip Pharma, Inc.$10,411,018
- James Cappo · National Jewish Health$9,298,220
- Rosianna R Gray · Stillman College$7,999,408
- Jeff T Hutchins · Inhalon Biopharma, Inc.$6,686,043
Research focus
Cause Of DeathStructureSuccessCessation Of LifeFutureMortalityEvaluationCareer DevelopmentCancer TypeCaringAdolescenceCancer TherapyCareerCareer ChoiceAdmission ActivityCancer RiskCancer ScienceCancer CareBasic Cancer ResearchCancer ControlCancer Death RatesCancer DiagnosisCancer PreventionCancer Biology
Grant awards (5)
Duke PRIME Cancer Research Program$217,729
R25 · FY2025 · CA
Duke PRIME Cancer Research Program$217,729
R25 · FY2024 · CA
Therapeutic Targeting of The Long Noncoding RNA SCHLAP1 in Aggressive Prostate Cancer$171,672
R21 · FY2024 · CA
Therapeutic Targeting of The Long Noncoding RNA SCHLAP1 in Aggressive Prostate Cancer$222,213
R21 · FY2023 · CA
Duke PRIME Cancer Research Program$196,839
R25 · FY2023 · CA